Screener
Stoke Therapeutics, Inc. STOK Other Non Program Costs Research And Development — Operating Expenses
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other external program costs | 3,178 | 1,829 |
| Payroll and other personnel costs - R&D (2) | 16,118 | 11,012 |
| Payroll and other personnel costs - SG&A (2) | 11,057 | 8,929 |
| Other non-program costs - R&D (3) | 1,680 | 1,407 |
| Other non-program costs - SG&A (3) | 5,156 | 4,788 |
| Interest expense | (23) | (1) |
| Interest income | 3,420 | 2,890 |
| Other income | 18 | 28 |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s other non program costs research and development — operating expenses?
- Stoke Therapeutics, Inc. (STOK) reported other non program costs research and development — operating expenses of -$1.68M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s other non program costs research and development — operating expenses changed year-over-year?
- Stoke Therapeutics, Inc.'s other non program costs research and development — operating expenses decreased by 19.4% year-over-year, from -$1.41M to -$1.68M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s other non program costs research and development — operating expenses?
- Over 2 years (2023 to 2025), Stoke Therapeutics, Inc.'s other non program costs research and development — operating expenses has grown at a 28.1% compound annual growth rate (CAGR), from -$3.74M to -$6.15M.
- What does other non program costs research and development — operating expenses mean?
- This metric represents the aggregate research and development expenditures that are not directly attributable to specific clinical programs or therapeutic candidates. It captures general overhead, infrastructure costs, and platform-wide research activities necessary to support the broader drug discovery pipeline. Monitoring these costs provides insight into the company's investment in foundational technology and administrative support for its research operations.
Ask your AI about Stoke Therapeutics, Inc.'s other non program costs research and development — operating expenses.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude